AERI Aerie Pharmaceuticals Inc

Price (delayed)

$13.23

Market cap

$624.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.61

Enterprise value

$780.89M

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. ...

Highlights
AERI's EPS is up by 18% YoY and by 5% from the previous quarter
The net income has grown by 18% year-on-year and by 5% since the previous quarter
AERI's gross margin is down by 6% year-on-year but it is up by 6% since the previous quarter
AERI's equity has dropped by 144% year-on-year
AERI's quick ratio is down by 33% year-on-year and by 16% since the previous quarter

Key stats

What are the main financial stats of AERI
Market
Shares outstanding
47.23M
Market cap
$624.9M
Enterprise value
$780.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.23
Earnings
Revenue
$94.92M
EBIT
-$161.11M
EBITDA
-$125.39M
Free cash flow
-$52.98M
Per share
EPS
-$3.61
Free cash flow per share
-$1.15
Book value per share
-$0.84
Revenue per share
$2.05
TBVPS
$7.7
Balance sheet
Total assets
$355.53M
Total liabilities
$395.14M
Debt
$235.94M
Equity
-$39.61M
Working capital
$180.93M
Liquidity
Debt to equity
-5.96
Current ratio
2.67
Quick ratio
2.29
Net debt/EBITDA
-1.24
Margins
EBITDA margin
-132.1%
Gross margin
73.9%
Net margin
-175.3%
Operating margin
-142.1%
Efficiency
Return on assets
-44.8%
Return on equity
-1,953.3%
Return on invested capital
-42.4%
Return on capital employed
-65.1%
Return on sales
-169.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AERI stock price

How has the Aerie Pharmaceuticals stock price performed over time
Intraday
-0.75%
1 week
5.08%
1 month
-15.73%
1 year
15.14%
YTD
-2.07%
QTD
16.05%

Financial performance

How have Aerie Pharmaceuticals's revenue and profit performed over time
Revenue
$94.92M
Gross profit
$70.13M
Operating income
-$134.92M
Net income
-$166.44M
Gross margin
73.9%
Net margin
-175.3%
The operating margin has grown by 36% YoY and by 17% from the previous quarter
Aerie Pharmaceuticals's net margin has increased by 29% YoY and by 15% from the previous quarter
The operating income is up by 25% year-on-year and by 8% since the previous quarter
The net income has grown by 18% year-on-year and by 5% since the previous quarter

Growth

What is Aerie Pharmaceuticals's growth rate over time

Valuation

What is Aerie Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
6.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.23
AERI's EPS is up by 18% YoY and by 5% from the previous quarter
AERI's equity has dropped by 144% year-on-year
The price to sales (P/S) is 17% less than the last 4 quarters average of 7.8
The company's revenue rose by 16% YoY and by 11% QoQ

Efficiency

How efficient is Aerie Pharmaceuticals business performance
AERI's ROS is up by 31% YoY and by 15% from the previous quarter
The ROIC has grown by 18% YoY and by 8% from the previous quarter
The ROA has grown by 4.1% YoY and by 3.4% from the previous quarter

Dividends

What is AERI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AERI.

Financial health

How did Aerie Pharmaceuticals financials performed over time
Aerie Pharmaceuticals's total assets is 10% lower than its total liabilities
The total liabilities has grown by 34% YoY and by 6% from the previous quarter
AERI's quick ratio is down by 33% year-on-year and by 16% since the previous quarter
AERI's equity has dropped by 144% year-on-year
AERI's debt to equity has surged by 73% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.